small molecule

HEXABRIX

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

Loss of exclusivity—loss of exclusivity

CompanyGuerbet →See this company's full patent-cliff portfolio

Drug detail

Brand name	HEXABRIX
Active ingredient	IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
Strength	39.3%;19.6%
Dosage form	INJECTABLE
Route	INJECTION
Modality	Small molecule
FDA approval	July 1985
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.